In addition, patient 2 is a CD19-positive R/R t(8;21) AML patient with c-KIT D816V mutation, which is recognized to an independent adverse prognostic factor in t(8; 21) AML and could significantly increase the risk of tumor recurrence (24). This evidence concerns the gene KIT and neoplasm.